Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West AfricaJohn Woodford, Patrick E. Duffy, Abdoulaye Katilé et al.|Frontiers in Immunology|2022Cited by 7